Essential fatty acid supplementation in chronic hepatitis B

Abstract

Dietary, supplementation with this dose of essential fatty acids is unlikely to be of benefit in chronic hepatitis B.

Essential Fatty Acids Status in Infants and Children with Chronic Liver Disease

“…Several investigators proposed that direct supplementation with LCP could provide a unique advantage in the correction of EFAs deficiency in patients with chronic liver diseases as well as end stage liver diseases [29,32,33]. Lepage et al [34] reported that ursodeoxycholic acid could improve the hepatic metabolism of EFAs and retinol in children with cystic fibrosis associated with liver disease as well as in cases of chronic hepatitis.…”

The effect of Oenothera biennis (Evening primrose) oil on inflammatory diseases: a systematic review of clinical trials

“…This constituted an overall reduction from baseline of approximately 58%. The profile of change during the open phase was comparable across the four treatment groups Digestive system disorders, respiratory system disorders, body in general—general disorders, reproductive system disorders, musculoskeletal system disorders, skin disorders 18 Pye [ 33 ] 6 months Overall, a grade I or II response was achieved in 165 (77%) of the 215 patients with cyclical mastalgia (danazol 70%, bromocriptine 47%, evening-primrose oil 45%, progestagens 15% Overall, a grade I or II response was achieved in 29 (44%) of the 66 patients with non-cyclical mastalgia (danazol 31%, bromocriptine 20%, evening-primrose oil 27%, progestagens 9% Effective 19 Qureshi [ 34 ] three months to 1 year. (over a period of one year) Results showed that out of 25 patients treated with OEP, 64% had a clinically significant response after three months of treatment, compared with 92% with topical NSAIDs abdominal bloating, nausea, weight gain, headache, depression, giddiness, rash and bad taste 20 Nasri [ 35 ] 12 weeks GSH (µmol/L) → EPO: 563.6 ± 138.4, Placebo: 470.5 ± 106 MDA(µmol/L) → EPO:2.1 ± 0.5, Placebo: 2.3 ± 0.8 GSH (µmol/L) → EPO: 626.3 ± 125.5, placebo: 469.8 ± 106.7 MDA(µmol/L) → EPO: 1.7 ± 0.4, placebo: 2.8 ± 1.6 significant increases in serum 25-hydroxyvitamin D (25(OH)D) (+ 10.7 ± 8.4 vs. − 0.5 ± 1.6 ng/mL, p < 0.001) and plasma total glutathione (GSH) (+ 62.7 ± 58.0 vs. − 0.7 ± 122.7 µmol/L, p = 0.01), while there were significant decreases in triglycerides (− 7.3 ± 23.8 vs. + 6.9 ± 26.3 mg/dL, p = 0.03), very low-density lipoprotein (VLDL) cholesterol levels (− 1.5 ± 4.7 vs. + 1.4 ± 5.3 mg/dL, p = 0.03), total/high-density lipoprotein cholesterol ratio (− 0.3 ± 0.4 vs. − 0.02 ± 0.4, p = 0.02), and malondialdehyde (MDA) concentration (− 0.4 ± 0.4 vs. + 0.5 ± 1.8 µmol/L, p = 0.008) No side effects were reported following supplementation throughout the study 21 Farzaneh [ 36 ] 6 weeks The percent of improvement in The frequency, severity and duration of hot flushes in the evening primrose group were 39, 42 and 19% compared to the placebo group, respectively 32, 32 and 18%.…”